ClinicalTrials.gg
CompletedNCT04111627Updated Oct 29, 2026Results posted

Exercise Plus Duloxetine for Knee Osteoarthritis

A Phase 2 interventional study of Aerobic exercise and Duloxetine in Knee Osteoarthritis and Depression, sponsored by University of Maryland, Baltimore. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Treatment

How we know

Updated Oct 29, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing duloxetine in Osteoarthritis, Knee — 4 open to participants now, 4 under way, none of them phase 3. duloxetine · Osteoarthritis, Knee.

Enrollment
16th of 19
43 · median 102
Started
2021
with 2 others
Phase 2
3 of 19
1 open now
Registered
10th of 19
by date

Among the 19 studies testing duloxetine in Osteoarthritis, Knee, this one is the 16th largest by enrollment, is one of 3 that started in 2021, is one of 3 in phase 2, and was the 10th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

4 of the 19 studies testing duloxetine in Osteoarthritis, Knee are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About duloxetine

duloxetine: first FDA approval 2004 (CYMBALTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing duloxetine in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

This study evaluates the addition of duloxetine to aerobic exercise in the treatment of symptomatic knee osteoarthritis and depressive symptoms in adults. All participants will receive the receive the treatment protocol, which will first be evaluated in terms of feasibility and then pilot tested.

Read the detailed description

Symptomatic knee osteoarthritis (OA) affects 10% of men and 13% of women 60 years or older, and depressive symptoms are common, occurring in one-fifth of these patients. Depressive symptoms worsen knee OA disease severity and are a barrier to pain management and engagement in physical activity. Guidelines recommend depression treatment in older adults with knee OA but provide no direction on how to simultaneously manage the co-occurrence of physical and mental morbidity. Treatment recommendations advise exercise to manage pain and disability and improve psychosocial health in knee OA patients; however, compliance to exercise programs is low in persons with chronic pain and disability and is only made worse by comorbid depression. Adherence is critical to the efficacy of depression treatments using exercise training, and no such exercise program has ever been designed for and tested in OA patients with co-occurring depressive symptoms in a way to enhance compliance. Duloxetine is the only antidepressant medication indicated for pain management in knee OA patients that has demonstrated efficacy and tolerability when treating depression in older adults and is a viable pharmacological complement to exercise. There are no protocols that combine treatments using interventions that affect symptoms of both knee OA and depression, and the study goals are to evaluate the feasibility of and then pilot test a protocol comprised of aerobic exercise training plus duloxetine for the treatment of symptomatic knee OA and comorbid depression.

03

Conditions studied

  • Knee Osteoarthritis
  • Depression
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. English speaking
  2. 40 years or older
  3. Symptomatic knee osteoarthritis fulfilling 1986 American College of Rheumatology criteria
  4. No plan for surgical knee osteoarthritis intervention within six months of enrollment
  5. Major depressive disorder satisfying diagnostic criteria according to the
  6. Ability to participate in a supervised aerobic exercise program

Exclusion criteria

Exclusion Criteria:

  1. Already performing aerobic or resistive exercise 2x/week or more
  2. Taking duloxetine, antipsychotics, benzodiazepines, or opioid analgesics
  3. Other medications deemed by study team to endanger the health of the participant or unduly confound the results
  4. Cognitive impairment ( score \< 20)
  5. Past or current bipolar disorder or psychotic symptoms according to the
  6. Substance abuse disorder or suicidal ideation within the previous year
  7. Not able to participate in a supervised exercise program based on the presence of unstable angina, recent MI (within last 3 months), hemiparetic gait, inability to walk at least 1mph on treadmill safely, poorly controlled hypertension (resting blood pressure > 190/110), peripheral arterial disease with current foot or leg ulcers, or cardiac or pulmonary disease with exercise tolerance class 3 or higher.
  8. Active cancer that is currently undergoing treatment (receiving chemotherapy and/or radiation therapy)
  9. Pregnant or lactating women
  10. Other conditions deemed by study team to endanger the health of the participant or unduly confound the results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Aerobic exercise plus Duloxetine

    Participants will have a starting duloxetine dosage of 30 mg/day and be titrated up to a daily optimal dosage of 60 mg/day as tolerated during the first 12-weeks of the study. Twelve weeks after the receipt of their prescription, participants will be evaluated for the need to increase medication dosage to 90 mg/day. After duloxetine initiation, participants will be provided an exercise prescription that includes a progressive walking program aiming to achieve 50 minutes of moderate-intensity physical activity, three times per week, over 24 weeks.

    Behavioral: Aerobic exercise · Drug: Duloxetine

Interventions

  • BehavioralAerobic exercise

    Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.

  • Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.

06

What researchers measure

Primary outcomes

  1. Knee Osteoarthritis Outcomes Scale (KOOS) Pain Subscale

    The self-reported KOOS pain subscale is sensitive to changes in knee OA symptoms, and consists of nine items scored on a Likert scale (0 \[No problems\] to 4 \[Extreme Problems\]) that ranges from 0-36, with higher values indicating greater severity.

    Time frame: Change from Baseline Pain Severity at 12 weeks

  2. Hamilton Depression Rating Scale (HAM-D)

    The HAM-D is clinician-administered, 21-item questionnaire, designed to rate the severity of depression in patients. Individual scores are based on the first 17 items, each with a possible score of 0-4 (0=Absent; 4=Extreme Symptoms) or 0-2 (0=Absent; 2=Frequent), yielding an overall range of 0-54. Higher scores indicate greater depression severity.

    Time frame: Change from Baseline Depression Severity at 12 weeks

07

Results

Posted Oct 29, 2026
Limitations and caveats
Both studies were small single-group feasibility studies without a comparison group. The center-based study had substantial screening exclusions and attrition and only one participant completed treatment. The subsequent hybrid study had improved retention, but clinical outcome analyses were limited to participants with available follow-up data. These limitations preclude conclusions regarding treatment efficacy.

Participant flow

Participants with symptomatic knee osteoarthritis and depressive symptoms were recruited from the University of Maryland Medical System, the Veterans Affairs Maryland Health Care System, and the surrounding Baltimore metropolitan area. Participants were enrolled sequentially into the center-based Duloxetine and Exercise for Knee Osteoarthritis and Depression (DEKODE) feasibility cohort and the subsequent hybrid Duloxetine and Exercise for Knee Osteoarthritis (DEKO) pilot cohort.

Participant flow — Overall Study
MilestoneCenter-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus Duloxetine
Started934
Completed117
Not completed817
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject17
Withdrew: Physician decision01
Withdrew: Protocol violation01
Withdrew: Did not meet eligibility criteria67
Withdrew: Adverse event10

Outcome measures

PrimaryKnee Osteoarthritis Outcomes Scale (KOOS) Pain Subscale

The self-reported KOOS pain subscale is sensitive to changes in knee OA symptoms, and consists of nine items scored on a Likert scale (0 \[No problems\] to 4 \[Extreme Problems\]) that ranges from 0-36, with higher values indicating greater severity.

Time frame:
Change from Baseline Pain Severity at 12 weeks
Reported as:
Mean · score
Knee Osteoarthritis Outcomes Scale (KOOS) Pain Subscale
scoreCenter-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus Duloxetine
Knee Osteoarthritis Outcomes Scale (KOOS) Pain Subscale2.814.2 ± 15.0
Statistical analysis
  • Hybrid Aerobic Exercise Plus Duloxetine · Two-sided paired t-test · p = 0.001267 · Mean within-participant change from base: 14.2 · 95% CI 6.5 to 21.9
PrimaryHamilton Depression Rating Scale (HAM-D)

The HAM-D is clinician-administered, 21-item questionnaire, designed to rate the severity of depression in patients. Individual scores are based on the first 17 items, each with a possible score of 0-4 (0=Absent; 4=Extreme Symptoms) or 0-2 (0=Absent; 2=Frequent), yielding an overall range of 0-54. Higher scores indicate greater depression severity.

Time frame:
Change from Baseline Depression Severity at 12 weeks
Reported as:
Mean · score
Hamilton Depression Rating Scale (HAM-D)
scoreCenter-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus Duloxetine
Hamilton Depression Rating Scale (HAM-D)-24-5.5 ± 6.8
Statistical analysis
  • Hybrid Aerobic Exercise Plus Duloxetine · Two-sided paired t-test. · p = 0.00413 · Mean within-participant change: -5.529 · 95% CI -9.0 to -2.0

Adverse events

Collected over Up to 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Center-Based Aerobic Exercise Plus Duloxetine0/9 (0%)0/9 (0%)2/9 (22.2%)
Hybrid Aerobic Exercise Plus Duloxetine0/34 (0%)0/34 (0%)10/34 (29.4%)
Most frequent other events
Most frequent other events
EventCenter-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus Duloxetine
Back painMusculoskeletal and connective tissue disorders1/90/34
Arrhythmia during graded exercise testCardiac disorders1/90/34
NauseaGastrointestinal disorders0/93/34
FallInjury, poisoning and procedural complications0/92/34
Stomach painGastrointestinal disorders0/92/34
Positive COVID testInfections and infestations0/91/34
Sexual dysfunctionReproductive system and breast disorders0/91/34
DrowsinessNervous system disorders0/91/34
Gastrointestinal symptomsGastrointestinal disorders0/91/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)Center-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus DuloxetineTotal
Mean64.7 ± 7.4061.4 ± 10.262.1 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Center-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus DuloxetineTotal
Female72229
Male21214
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Center-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus DuloxetineTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American81624
White11617
More than one race011
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Center-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus DuloxetineTotal
Hispanic or Latino022
Not Hispanic or Latino93241
Unknown or Not Reported000
Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain
Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain(score)Center-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus DuloxetineTotal
Mean41.7 ± 049.34 ± 14.5448.7 ± 14.0
6-Minute Walk Distance
6-Minute Walk Distance(feet)Center-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus DuloxetineTotal
Mean—1222.6 ± 250.81222.6 ± 250.8
30-Second Chair Stand Test
30-Second Chair Stand Test(stands)Center-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus DuloxetineTotal
Mean—9.1 ± 3.29.1 ± 3.2
Timed Up and Go Test
Timed Up and Go Test(seconds)Center-Based Aerobic Exercise Plus DuloxetineHybrid Aerobic Exercise Plus DuloxetineTotal
Mean—12.0 ± 3.212.0 ± 3.2

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
09

References and documents

Publications

  • Rathbun AM, Ryan AS, Dong Y, Beamer BA, Luborsky M, Shardell MD, Golden J, Campbell CM, Lo GH, Peer JE, Hochberg MC. Pilot study of duloxetine plus aerobic exercise for pain and depressive symptoms in knee osteoarthritis. Rheumatol Adv Pract. 2026 Oct 6;10(4):rkag116. doi: 10.1093/rap/rkag116. eCollection 2026. PubMed 42936867 ↗
  • Rathbun AM, Mehta R, Ryan AS, Dong Y, Beamer B, Golden J, Gallo JJ, Luborsky M, Shardell MD, Peer JE, Hochberg MC. Duloxetine plus exercise for knee osteoarthritis and depression: A feasibility study. Osteoarthr Cartil Open. 2023 Dec 8;6(1):100426. doi: 10.1016/j.ocarto.2023.100426. eCollection 2024 Mar. PubMed 38130375 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Aug 2025, 46 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 43 non-industry phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's 46 months is above that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2019
First posted
Oct 1, 2019
StartActual
Oct 7, 2021
Primary completionActual
Aug 11, 2025
CompletionActual
Aug 11, 2025
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedKnee Osteoarthritis Outcomes Scale (KOOS) pain subscalePain SubscaleTime frame: Change from Baseline Pain Severity at 12 weeks
Oct 29, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42936867 ↗
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42936867 ↗
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedKnee Osteoarthritis Outcomes Scale (KOOS) pain subscalePain SubscaleTime frame: Change from Baseline Pain Severity at 12 weeks
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04111627
Responsible party
Alan Rathbun (Assistant Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Oct 1, 2019
Start date
Oct 7, 2021
Primary completion
Aug 11, 2025
Completion
Aug 11, 2025
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duloxetine

Start the discussion